About Us

Kinomica is a proteomic-data science and diagnostics company specialising in cell signalling. We offer KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. 

We offer KScan™ for:

  1. Improved monitoring of drug molecular efficacy and response (to fully elucidate mode of action and mechanisms of resistance).
  2. Discovery of predictive biomarkers for patient selection and stratification in clinical trials.

Kinomica’s approach to measuring the phosphorylation signature of proteins, rather than using gene expression, provides a direct snapshot of protein and cell-signalling activity. We have preclinical proof-of-concept data to demonstrate that our game-changing biomarkers predict drug response more accurately than current state-of-the-art gene sequencing.

Technology

KScan™, the phosphoproteomics platform developed by Kinomica’s founders, has the potential to predict patient responses to targeted therapies with greater accuracy than currently possible.

KScan™ directly measures intracellular kinase and cell-signalling pathway activity in cells and tissues and combines the phosphoproteomics readout with innovative computational (including machine-learning) algorithms and high-quality data to reveal drug molecular efficacy, mechanisms of action and therapeutic resistance; identify and validate new biomarkers; inform clinical and diagnostic decision-making; and identify novel and/or alternative drug targets and therapies.

KScan™ offering can be tailored to provide a range of services to meet specific customer needs and is being developed further as a companion diagnostic technology to guide physicians in the selection of effective treatment for each individual patient, facilitating enhanced precision medicine. 

Publications

Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line.

Cutillas PR, Geering B, Waterfield MD, Vanhaesebroeck B.

Quantitative profile of five murine core proteomes using label-free functional proteomics.

Cutillas PR, Vanhaesebroeck B.

A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.

Casado P, Cutillas PR.

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.

Casado P, Rodriguez-Prados JC, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S, Cutillas PR.

Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability.

Wilkes EH, Casado P, Rajeeve V, Cutillas PR.

Empirical inference of circuitry and plasticity in a kinase signaling network.

Wilkes EH, Terfve C, Gribben JG, Saez-Rodriguez J, Cutillas PR.

Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.

Alcolea MP, Casado P, Rodríguez-Prados JC, Vanhaesebroeck B, Cutillas PR.

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.

Casado P, Rodriguez-Prados JC, Cosulich SC, Guichard S, Vanhaesebroeck B, Joel S, Cutillas PR.

Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability.

Wilkes EH, Casado P, Rajeeve V, Cutillas PR.

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.

Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S, Marfa S, Lea N, Best S, Gribben J, Fitzgibbon J, Cutillas PR.

People

Our Team

Jane Theaker

Jane Theaker


CEO

Jane Theaker

CEO

CEO of Kinomica, is an executive and strategist with a proven track record and more than 20 years of experience leading teams in pharma and diagnostics. Jane has implemented numerous genomic technologies to support drug discovery and development and developed several FDA-approved companion diagnostics tests.

Marie Ann Roskrow

Marie Ann Roskrow


Chairperson

Marie Ann Roskrow

Chairperson

Dr Roskrow gained a BSc (Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 9years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Marie is currently Chairman of Biotec Pharmacon, a publicly-listed Norwegian life-sciences company.

David Britton

David Britton


co-Founder & CSO

David Britton

co-Founder & CSO

co-Founder and CSO of Kinomica, previously held academic positions in the field of oncology at Cardiff University, The Buck Institute and Barts Cancer Institute (Queen Mary University London). David helped to develop KScan™ after gaining industrial experience at Thermo Fisher Scientific and Proteome Sciences, specialising in mass spectrometry and proteomics.

Pedro Cutillas

Pedro Cutillas


co-Founder & Consultant

Pedro Cutillas

co-Founder & Consultant

Dr Pedro Cutillas is a co-Founder and main inventor of the technology. Pedro is a Reader and Principal Investigator at Barts Cancer Institute, QMUL, and a Fellow of the Turing Institute. With over 50 publications and 8 patents, Pedro is a leading expert in the development and application of proteomics and bioinformatics approaches to understand signalling networks in cancer. Pedro is also an experienced entrepreneur - his research led to the establishment in 2011 of Activiomics Ltd, a spin-out from Barts School of Medicine, for which he was academic co-Founder and Non-Executive Director. Activiomics was acquired in 2014 by hVivo for £4M. Pedro will retain his academic position but consults under private contract to Kinomica to technically advise and support the platform and software on which Kinomica is founded.

Arran Dokal

Arran Dokal


Senior Scientist

Arran Dokal

Senior Scientist

Senior Scientist for Kinomica, has previously held academic positions at the Barts Cancer Institute (Queen Mary University) specialising in the use of bioinformatic approaches to understand the nature of kinase signalling in cancer. Prior to completing his PhD under the tutelage of Pedro Cutillas and Professor John Gribben, Arran gained industrial experience in providing high quality drug discovery services working at Xention (now Metrion Biosciences).

Ryan Smith

Ryan Smith


Senior Scientist

Ryan Smith

Senior Scientist

Senior Scientist for Kinomica, graduated in Physics at Queen Mary University where he completed his PhD focusing on the development of novel algorithms and computational solutions for large-scale phosphoproteomics experiments. Ryan has held academic positions in the group of Pedro Cutillas at Barts Cancer Institute both as a PhD student and as a Postdoctoral Researcher before eventually joining Kinomica.

Our Investors

Michele Hill Perkins

Michele Hill Perkins


Investor - QMUL

Michele Hill Perkins

Investor - QMUL

Michele started her career as a research scientist in academia and then the biotechnology industry. She has held senior business development roles at Cancer Research Technology and the Wellcome Trust where she was involved in licensing transactions and the provision of “development gap” funding to spin-out companies in the biotechnology and pharmaceutical sector. Prior to joining QMI, Michele worked as Project Director at Partnerships UK in the science commercialisation team, advising public sector organisations on commercial strategy, and also in its venture capital arm, PUK Ventures, advising on life science and medtech investments. Michele was investment manager at the Children’s Investment Fund Foundation responsible for investments in child survival. Michele has a PhD in biochemistry, an MSc from University College, London and an MA (Oxon) in Human Sciences.

Claire Brown

Claire Brown


Investor - Biocity

Claire Brown

Investor - Biocity

Claire currently leads BioCity's investment activity making seed stage investments into early healthcare companies. The company make off-balance sheet investments as well as management of a dedicated life science seed fund, Alderley Park Ventures Ltd. Since joining in 2015 She has led the majority of the investments in the Company’s broad portfolio spanning therapeutic platforms to medical devices & industrial Biotech and currently serves on the boards of a number of portfolio companies, including Fast BioPharma, Metalinear, Rinri Therapeutics and Kinomica Ltd.

Will Chawner

Will Chawner


Investor - Puffin Point

Will Chawner

Investor - Puffin Point

Puffin Point is a single family office based in London and focused primarily on public and private equity investments. Our portfolio includes businesses across a wide spectrum of industry sectors.

News

Biocity and Innovate UK invest in Kinomica

Cheshire UK, 29 August 2019


BioCity, the pioneering life science incubator and business collective, announced investment in precision medicine biotech, Kinomica Ltd, via the Innovate UK Precision Medicine Investment Accelerator.

https://biocity.co.uk/biocity-invests-in-early-stage-precision-medicine-biotech/

Contact Us